Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
2.

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.

Rocco D, Gravara LD, Gridelli C.

Curr Clin Pharmacol. 2019 Aug 9. doi: 10.2174/1574884714666190809124555. [Epub ahead of print]

PMID:
31400270
3.

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.

Morabito A, Piccirillo MC, Maione P, Luciani A, Cavanna L, Bonanno L, Filipazzi V, Leo S, Cinieri S, Morgillo F, Burgio MA, Ferrara D, Rosetti F, Bianco R, Artioli F, Cortinovis D, Gebbia V, Fregoni V, Mencoboni M, Sandomenico C, Rossi A, Montanino A, Manzo A, Rocco G, Arenare L, Daniele G, Signoriello S, Gallo C, Perrone F, Gridelli C.

Lung Cancer. 2019 Jul;133:62-68. doi: 10.1016/j.lungcan.2019.05.009. Epub 2019 May 9.

PMID:
31200830
4.

The role of combination chemo-immunotherapy in advanced non-small cell lung cancer.

Rocco D, Della Gravara L, Battiloro C, Gridelli C.

Expert Rev Anticancer Ther. 2019 Jul;19(7):561-568. doi: 10.1080/14737140.2019.1631800. Epub 2019 Jun 25.

PMID:
31188040
5.

Combining immunotherapies to treat non-small cell lung cancer.

Spagnuolo A, Gridelli C.

Expert Rev Respir Med. 2019 Jul;13(7):621-634. doi: 10.1080/17476348.2019.1623027. Epub 2019 May 29.

PMID:
31116072
6.

First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development.

Rocco D, Della Gravara L, Battiloro C, Gridelli C.

Expert Rev Respir Med. 2019 Mar 28:1-7. doi: 10.1080/17476348.2019.1600824. [Epub ahead of print]

PMID:
30920858
7.

Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Casaluce F, Gridelli C.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S370-S372. doi: 10.21037/tlcr.2018.09.18. No abstract available.

8.

The combination strategies will be ready the right first-line choice for squamous lung cancer patients?

Gridelli C, Casaluce F.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S349-S351. doi: 10.21037/tlcr.2018.11.02. No abstract available.

9.

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.

Rocco D, Battiloro C, Della Gravara L, Gridelli C.

Drug Saf. 2019 Feb;42(2):199-209. doi: 10.1007/s40264-018-0771-y. Review.

PMID:
30649741
10.

Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice.

De Marinis F, Barberis M, Barbieri V, Marchianò A, Gasparini S, Migliorino MR, Romano G, Spinnato F, Vitiello F, Gridelli C.

Expert Rev Respir Med. 2019 Mar;13(3):217-228. doi: 10.1080/17476348.2019.1569517. Epub 2019 Jan 24.

PMID:
30640563
11.

"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?

Spagnuolo A, Gridelli C.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4065-S4068. doi: 10.21037/jtd.2018.09.83. No abstract available.

12.

Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond.

Rocco D, Battiloro C, Gravara LD, Gridelli C.

Rev Recent Clin Trials. 2019;14(2):120-128. doi: 10.2174/1574887114666181205155211.

PMID:
30520383
13.

Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?

Casiraghi M, Guarize J, Sandri A, Maisonneuve P, Brambilla D, Romano R, Galetta D, Petrella F, Gasparri R, Gridelli C, De Marinis F, Spaggiari L.

Clin Lung Cancer. 2019 Mar;20(2):97-106.e1. doi: 10.1016/j.cllc.2018.10.005. Epub 2018 Oct 24.

PMID:
30446406
14.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.

N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.

15.

Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.

Spagnuolo A, Maione P, Gridelli C.

Expert Opin Emerg Drugs. 2018 Sep;23(3):231-241. doi: 10.1080/14728214.2018.1527902. Epub 2018 Oct 15. Review.

PMID:
30251885
16.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.

Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J.

JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

17.

What pharmacotherapeutics should one use for early stage non-small cell lung cancer?

Battiloro C, Della Gravara L, Rocco D, Gridelli C.

Expert Opin Pharmacother. 2018 Sep;19(13):1403-1406. doi: 10.1080/14656566.2018.1510915. Epub 2018 Aug 16. No abstract available.

PMID:
30113230
18.

Treatment of advanced non-small cell lung cancer in the elderly.

Sacco PC, Maione P, Palazzolo G, Gridelli C.

Expert Rev Respir Med. 2018 Sep;12(9):783-792. doi: 10.1080/17476348.2018.1510322. Epub 2018 Aug 21. Review.

PMID:
30092728
19.

Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.

Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Filipazzi V, Leo S, Cinieri S, Ciardiello F, Burgio MA, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo MC, Gallo C, Perrone F.

J Clin Oncol. 2018 Sep 1;36(25):2585-2592. doi: 10.1200/JCO.2017.76.8390. Epub 2018 Jul 20.

PMID:
30028656
20.

Lung cancer resection in octogenarian patients.

Spaggiari L, Petrella F, Maione P, Gridelli C.

J Thorac Dis. 2018 Jun;10(Suppl 17):S1995-S1997. doi: 10.21037/jtd.2018.05.39. No abstract available.

21.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

22.

Frontline immunotherapy for NSCLC: alone or not alone?

Gridelli C, Casaluce F.

Nat Rev Clin Oncol. 2018 Oct;15(10):593-594. doi: 10.1038/s41571-018-0070-7. No abstract available.

PMID:
29993034
23.

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

Gridelli C, Ascierto PA, Grossi F, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F.

Curr Clin Pharmacol. 2018;13(2):76-84. doi: 10.2174/1574884713666180711160008.

PMID:
29992894
24.

Lung cancer, elderly and immune checkpoint inhibitors.

Casaluce F, Sgambato A, Maione P, Spagnuolo A, Gridelli C.

J Thorac Dis. 2018 May;10(Suppl 13):S1474-S1481. doi: 10.21037/jtd.2018.05.90. Review.

25.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

26.

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.

Gridelli C, Chen T, Ko A, O'Brien ME, Ong TJ, Socinski MA, Postmus PE.

Drug Des Devel Ther. 2018 May 24;12:1445-1451. doi: 10.2147/DDDT.S155750. eCollection 2018.

27.

Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial.

Spadafora M, Pace L, Evangelista L, Mansi L, Del Prete F, Saladini G, Miletto P, Fanti S, Del Vecchio S, Guerra L, Pepe G, Peluso G, Nicolai E, Storto G, Ferdeghini M, Giordano A, Farsad M, Schillaci O, Gridelli C, Cuocolo A.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1908-1914. doi: 10.1007/s00259-018-4043-y. Epub 2018 May 5.

PMID:
29730697
28.

J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?

Gridelli C, Casaluce F, Sgambato A, Palazzolo G, Maione P.

J Thorac Dis. 2018 Jan;10(1):106-108. doi: 10.21037/jtd.2017.12.76. No abstract available.

29.

Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Visseren-Grul CM, San Antonio B, John WJ, Zimmermann AH, Chouaki N, Paz-Ares L.

Curr Med Res Opin. 2018 May;34(5):865-871. doi: 10.1080/03007995.2018.1439462. Epub 2018 Mar 27.

PMID:
29424248
30.

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.

Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.cllc.2017.12.010. Epub 2017 Dec 22. Review.

PMID:
29396237
31.

The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?

Troncone G, Gridelli C.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S74-S77. doi: 10.21037/tlcr.2017.10.05. No abstract available.

32.

Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.

Sgambato A, Casaluce F, Maione P, Gridelli C.

Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6. Review.

PMID:
29187012
33.

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.

Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C.

Lung Cancer (Auckl). 2017 Oct 30;8:207-216. doi: 10.2147/LCTT.S138570. eCollection 2017.

34.

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.

Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leighl N, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C.

Oncotarget. 2017 Feb 25;8(34):57528-57536. doi: 10.18632/oncotarget.15725. eCollection 2017 Aug 22.

35.

An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.

Sacco PC, Gridelli C.

Expert Opin Emerg Drugs. 2017 Sep;22(3):213-222. doi: 10.1080/14728214.2017.1369952. Review.

PMID:
28836854
36.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F.

Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. Review.

37.

Selumetinib for the treatment of non-small cell lung cancer.

Casaluce F, Sgambato A, Maione P, Sacco PC, Santabarbara G, Gridelli C.

Expert Opin Investig Drugs. 2017 Aug;26(8):973-984. doi: 10.1080/13543784.2017.1351543. Epub 2017 Jul 12. Review.

PMID:
28675058
38.

Recent advances in targeted advanced lung cancer therapy in the elderly.

Losanno T, Gridelli C.

Expert Rev Anticancer Ther. 2017 Sep;17(9):787-797. doi: 10.1080/14737140.2017.1348232. Epub 2017 Jul 4. Review.

PMID:
28656792
39.

A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.

Morabito A, Daniele G, Costanzo R, Favaretto AG, Filipazzi V, Rossi A, Gebbia V, Castiglione F, Cavanna L, Maiello E, Sandomenico C, Bonanno L, Piazza E, Maione P, Piccirillo MC, Di Maio M, Rocco G, Gallo C, Perrone F, Gridelli C.

Lung Cancer. 2017 Jun;108:15-21. doi: 10.1016/j.lungcan.2017.02.016. Epub 2017 Feb 27.

PMID:
28625627
40.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E.

Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9.

PMID:
28602779
41.

Alternative imaging strategy of solitary pulmonary nodule by FDG PET/CT: Can be imagined a tailored PET?

Spadafora M, Evangelista L, Gridelli C, Cuocolo A.

Eur J Radiol. 2017 May;90:188-191. doi: 10.1016/j.ejrad.2017.03.001. Epub 2017 Mar 7.

PMID:
28583632
42.

Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.

Langer CJ, Paz-Ares LG, Wozniak AJ, Gridelli C, de Marinis F, Pujol JL, San Antonio B, Chen J, Liu J, Oton AB, Visseren-Grul C, Scagliotti GV.

Clin Lung Cancer. 2017 Sep;18(5):489-496. doi: 10.1016/j.cllc.2017.04.003. Epub 2017 Apr 12.

PMID:
28479368
43.

EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.

DE Marinis F, Bidoli P, Luciani A, Amoroso D, Tonini G, Bertolini A, Brandes AA, Migliorino MR, Favaretto A, Gridelli C.

Anticancer Res. 2017 May;37(5):2457-2464.

PMID:
28476814
44.

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.

Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, McCusker ME.

PLoS One. 2017 Apr 14;12(4):e0175679. doi: 10.1371/journal.pone.0175679. eCollection 2017. Review.

45.

The safety of second-line treatment options for non-small cell lung cancer.

Rossi A, Maione P, Santabarbara G, Sacco PC, Casaluce F, Sgambato A, Barzelloni ML, Palazzolo G, Gridelli C.

Expert Opin Drug Saf. 2017 Apr;16(4):471-479. doi: 10.1080/14740338.2017.1297795. Epub 2017 Mar 1. Review.

PMID:
28276858
46.

The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.

Sgambato A, Casaluce F, Gridelli C.

Expert Opin Biol Ther. 2017 May;17(5):565-571. doi: 10.1080/14712598.2017.1294157. Epub 2017 Feb 20. Review.

PMID:
28276698
47.

Developments in pharmacotherapy for treating metastatic non-small cell lung cancer.

Rossi A, Sacco PC, Santabarbara G, Sgambato A, Casaluce F, Palazzolo G, Maione P, Gridelli C.

Expert Opin Pharmacother. 2017 Feb;18(2):151-163. doi: 10.1080/14656566.2017.1280460. Epub 2017 Jan 20. Review.

PMID:
28067062
48.

A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting.

Gridelli C, Losanno T.

J Thorac Dis. 2016 Nov;8(11):E1520-E1524. doi: 10.21037/jtd.2016.11.91. No abstract available.

49.

Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC).

Gridelli C, Camerini A, Pappagallo G, Pennella A, Anzidei M, Bellomi M, Buosi R, Grasso RF.

Cancer Imaging. 2016 Dec 28;16(1):44. doi: 10.1186/s40644-016-0102-4.

50.

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

Pacchiana MV, Capelletto E, Carnio S, Gridelli C, Rossi A, Galetta D, Montagna ES, Bordi P, Ceribelli A, Cortinovis D, Scotti V, Martelli O, Valmadre G, Del Conte A, Miccianza A, Morena R, Rosetti F, Di Maio M, Ostacoli L, Novello S.

Clin Lung Cancer. 2017 Jul;18(4):381-387. doi: 10.1016/j.cllc.2016.10.002. Epub 2016 Nov 22.

PMID:
27965013

Supplemental Content

Loading ...
Support Center